M Machado
Overview
Explore the profile of M Machado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz-Garcia J, Gomez A, Machado M, Alcala L, Reigadas E, Sanchez-Carrillo C, et al.
Rev Esp Quimioter
. 2023 Jun;
36(5):541-544.
PMID: 37355994
No abstract available.
2.
Cobos A, Valerio M, Palomo M, Adan I, Catalan P, Veintimilla C, et al.
Rev Esp Quimioter
. 2023 Jan;
36(2):194-200.
PMID: 36651283
The present outbreak of Human Monkeypox (HMPX) that has begun in May 2022 and has spread across all continents in less than two months has qualitative and quantitative characteristics that...
3.
Almeida A, Correia T, Pires R, da Silva D, Coqueiro R, Machado M, et al.
Braz J Med Biol Res
. 2022 Aug;
55:e12116.
PMID: 35976270
Cisplatin is an effective antineoplastic agent, but its use is limited by its nephrotoxicity caused by the oxidative stress in tubular epithelium of nephrons. On the other hand, regular exercise...
4.
Criscuolo M, Salmanton-Garcia J, Fracchiolla N, Dragonetti G, Khanna N, Weinbergerova B, et al.
J Investig Allergol Clin Immunol
. 2022 Jul;
33(3):225-227.
PMID: 35894666
No abstract available.
5.
Moreno-Garcia E, Puerta-Alcalde P, Gariup G, Fernandez-Ruiz M, Lopez Cortes L, Cuervo G, et al.
Open Forum Infect Dis
. 2022 May;
9(6):ofac180.
PMID: 35615301
[This corrects the article DOI: 10.1093/ofid/ofab250.].
6.
Olmedo M, Kestler M, Valerio M, Padilla B, Rodriguez Gonzalez C, Chamarro E, et al.
Rev Esp Quimioter
. 2022 Mar;
35(3):279-283.
PMID: 35279984
Objective: Following the approval of bezlotoxumab in 2017, studies evaluating its effectiveness in prevention of Clostridioides difficile infection under "real-life" conditions are scarce. Methods: We conducted a retrospective study developed...
7.
Gudiol C, Dura-Miralles X, Aguilar-Company J, Hernandez-Jimenez P, Martinez-Cutillas M, Fernandez-Aviles F, et al.
J Infect
. 2021 Jul;
83(3):306-313.
PMID: 34302864
Background: We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections and superinfections in onco-hematological patients with COVID-19. Methods: International, multicentre cohort study of cancer patients with...
8.
Moreno-Garcia E, Puerta-Alcalde P, Gariup G, Fernandez-Ruiz M, Lopez Cortes L, Cuervo G, et al.
Open Forum Infect Dis
. 2021 Jun;
8(6):ofab250.
PMID: 34104670
Background: There are no clear criteria for antifungal de-escalation after initial empirical treatments. We hypothesized that early de-escalation (ED) (within 5 days) to fluconazole is safe in fluconazole-susceptible candidemia with...
9.
Albasanz-Puig A, Gudiol C, Puerta-Alcalde P, Ayaz C, Machado M, Herrera F, et al.
Antimicrob Agents Chemother
. 2021 May;
65(8):e0004521.
PMID: 33972253
To test the hypothesis that the addition of an aminoglycoside to a β-lactam antibiotic could provide better outcomes than β-lactam monotherapy for the initial empirical treatment of hematological neutropenic patients...
10.
Grenho-Rodrigues S, Silva D, Machado M, Roque R, Pimentel J
Rev Neurol
. 2021 Apr;
72(8):283-287.
PMID: 33851717
Introduction: Background And Aim: Muscle biopsy is still an important exam on the investigation of neuromuscular diseases although data regarding its diagnostic yield can be disappointing. We aimed to analyze...